"CYNA is now well funded, NASDAQ-listed and liquid; it isdefinitely among my better ideas as of today." (7/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Jason Napodano More >
"BCLI has what looks to be a safe and potentially effective treatment for delaying disease progression in patients with ALS." (7/8/15) BrainStorm Cell Therapeutics Inc. - The Life Sciences Report Interview with Jason Napodano More >
"If results from RVX's Phase 3 program are positive, the stock could have a significant revaluation to much higher levels." (7/8/15) Resverlogix Corp. - The Life Sciences Report Interview with Jason Napodano More >
Subscribe to Streetwise Reports’ Newsletters
Receive weekly insight into today’s investment ideas from leading analysts and experts.
To make sure our emails arrive in your inbox, please add firstname.lastname@example.org to your "safe sender" list. If you are unsure how to whitelist or add someone to your safe senders list, please follow the instructions here.
"INO has a broad platform that includes an IL-12 DNA vaccine and other DNA vaccines for both cancer and infectious diseases." (6/24/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >
"The intriguing component of SNSS' VALOR study is a nice survival benefit seen in patients 60 years and older." (6/17/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Joe Pantginis More >
"Following the 12-week endpoint, CANF's CF101 continued accumulation and the responses have become much better." (6/17/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Joe Pantginis More >